Breakthroughs in Alzheimer's Treatment: Patented Treatments Show Promise

Strategic Insights -

Researchers at the Blanchette Rockefeller Neurosciences Institute have made significant progress in developing new treatments for Alzheimer's disease. The institute has patented two novel approaches, one using bryostatin, a cancer treatment drug, and the other combining methylxanthine and phenylalanine. Initial lab animal studies suggest that these treatments can reverse memory loss symptoms and potentially prevent the disease. Clinical trials are set to commence in the next 6-8 months, paving the way for further testing and potential approval for human use.

Key Takeaways:

  • The Blanchette Rockefeller Neurosciences Institute has patented two new treatments for Alzheimer's disease: one using bryostatin and the other combining methylxanthine and phenylalanine.
  • Bryostatin activates an enzyme, which reduces the growth of certain brain plaques thought to cause Alzheimer's, and may even prevent the disease.
  • The combination of methylxanthine and phenylalanine appears to improve short-term memory and may also be used to treat attention-deficit disorder.
  • Clinical trials are set to start in 6-8 months, using substances already approved for human use, with the goal of determining their safety and effectiveness.
  • The treatments build on previous research at the institute into how brain molecules interact to form memory.
  • About 40,000 West Virginians and over 4 million Americans are affected by Alzheimer's.
  • The research team consists of about 25 scientists working in labs at West Virginia University and Johns Hopkins University in Baltimore.
  • The institute's nonprofit status is thanks to the efforts of Senator Jay Rockefeller, who founded it in memory of his mother, who battled Alzheimer's before her death in 1992.

Statistics:

  • 40,000: The number of West Virginians affected by Alzheimer's.
  • 4 million: The number of Americans affected by Alzheimer's.
  • 25: The number of researchers working at the institute.
  • 6-8 months: The projected timeframe for clinical trials to commence.
  • 1999: The year Senator Jay Rockefeller founded the nonprofit institute.
  • 1992: The year Senator Jay Rockefeller's mother passed away due to Alzheimer's.
  • $30 million: The cost of the new building at West Virginia University being constructed for the institute.

Sources:

  • Health & Medicine Week
  • NewsRx.com & NewsRx.net
  • Blanchette Rockefeller Neurosciences Institute
  • West Virginia University
  • Johns Hopkins University
  • NewsRx.com & NewsRx.net (U.S. Patent and Trademark Office)